NGM NGM Biopharmaceuticals Inc.

17.17
+0.59  (+4%)
Previous Close 16.58
Open 16.66
Price To Book 3.37
Market Cap 1,144,459,293
Shares 66,654,589
Volume 171,472
Short Ratio
Av. Daily Volume 188,379
Stock charts supplied by TradingView

NewsSee all news

  1. NGM Bio Announces Appointment of Shelly Guyer to Board of Directors

    SOUTH SAN FRANCISCO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NASDAQ:NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today

  2. NGM Bio to Present at the Stifel 2019 Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NASDAQ:NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today

  3. NGM Reports Business Highlights and Third Quarter 2019 Financial Results

    --Announced positive interim results from ongoing 24-week Phase 2 study evaluating-- --1 mg aldafermin (formerly NGM282) (Cohort 4) in non-alcoholic steatohepatitis (NASH) patients--  --Anticipates full Cohort 4 data,

  4. NGM Bio Announces Appointment of Valerie Pierce as General Counsel

    SOUTH SAN FRANCISCO, Calif., Oct. 29, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NASDAQ:NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today

  5. NGM Bio to Present at Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Oct. 18, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NASDAQ:NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1a/1b trial to be initiated 2H 2019.
NGM120
Cachexia syndrome
Phase 2 trial to be initiated 2020.
NGM313 / MK-3655
Non-alcoholic steatohepatitis (NASH) and Type 2 diabetes
Phase 1 trial initiated 2Q 2019.
NGM621
Geographic atrophy
Phase 2 full Cohort 4 data due 1Q 2020.
NGM282
Non-alcoholic steatohepatitis (NASH)
Phase 2b initial data due by the end of 2020.
NGM282 - ALPINE 2/3
Non-alcoholic steatohepatitis (NASH)

Latest News

  1. NGM Bio Announces Appointment of Shelly Guyer to Board of Directors

    SOUTH SAN FRANCISCO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NASDAQ:NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today

  2. NGM Bio to Present at the Stifel 2019 Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NASDAQ:NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today

  3. NGM Reports Business Highlights and Third Quarter 2019 Financial Results

    --Announced positive interim results from ongoing 24-week Phase 2 study evaluating-- --1 mg aldafermin (formerly NGM282) (Cohort 4) in non-alcoholic steatohepatitis (NASH) patients--  --Anticipates full Cohort 4 data,

  4. NGM Bio Announces Appointment of Valerie Pierce as General Counsel

    SOUTH SAN FRANCISCO, Calif., Oct. 29, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NASDAQ:NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today

  5. NGM Bio to Present at Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Oct. 18, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NASDAQ:NGM), a clinical stage biotechnology company focused on developing transformative therapeutics for patients, today

  6. NGM Bio Announces Positive Interim Results from Ongoing 24-Week Phase 2 Study Evaluating Aldafermin (NGM282) in Patients with NASH

    --Treatment with aldafermin 1 mg resulted in statistically significant reductions in absolute and relative liver fat at 24 weeks compared to placebo -- -- Statistically significant improvements also observed across key

  7. NGM Bio Announces Positive Interim Results from Ongoing 24-Week Phase 2 Study Evaluating Aldafermin (NGM282) in Patients with NASH

    --Treatment with aldafermin 1 mg resulted in statistically significant reductions in absolute and relative liver fat at 24 weeks compared to placebo -- -- Statistically significant improvements also observed across key

  8. NGM Bio to Host Conference Call to Discuss Interim Results from Ongoing 24-Week Phase 2 Study of Aldafermin (NGM282) in Patients with NASH

    SOUTH SAN FRANCISCO, Calif., Oct. 06, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) will host a conference call and live webcast on Monday, October 7, 2019 at 8:30 a.m. ET (5:30 a.m. PT) to discuss

  9. NGM Bio Announces Multiple Aldafermin (NGM282) Poster Presentations at Upcoming AASLD's The Liver Meeting®

    SOUTH SAN FRANCISCO, Calif., Oct. 03, 2019 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NASDAQ:NGM), a clinical stage biotechnology company focused on harnessing powerful biology to develop transformative